An estimated 25 million Americans suffer from Asthma, but current medications such as inhalers have been deemed ineffective for 10-20% of its users. Regneron (REGN) and Sanofi (SAN) have partnered to crease a new Asthma drug, Dupilumab. In their most recent Phase IIa trial, 87% of patients showed less asthma attacks or other symptomatic outbreaks compared with those patients receiving the placebo. The New England Journal of Medicine stated it is “too early to tell if this therapy will be of clinical value, though it is probably on the right track.” The Phase IIb trial is expected to begin mid 2013 and at this rate market release is expected within the next 2-3 years.
Through our news, radio interviews, video production, and research, OneMedPlace specializes in delivering information to investors covering nanocap, microcap and private emerging growth companies in the hottest areas of life sciences. OneMedPlace covers what we believe to be an undervalued sector, and has built a network of investors at all levels of financial and strategic development. OneMedPlace produces two investor conferences, OneMedForumSF in January and OneMedForumNY in June, bringing together our diverse network to meet the most promising companies in life sciences. Visit our website to learn more about attending.